Neo Ivy Capital Management Beam Therapeutics Inc. Transaction History

Neo Ivy Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$29.86 - $62.36 $259,722 - $542,407	-8,698 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $467,343 - $714,627	8,698 New	8,698 $498,000
Q3 2021 Nov 16, 2021	SELL	$84.37 - $133.6 $82,851 - $131,195	-982 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $7,181 - $14,415	-112 Reduced 10.24%	982 $126,000
Q1 2021 Oct 07, 2021	BUY	$71.28 - $120.75 $77,980 - $132,100	1,094 New	1,094 $88,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.7B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.